Best Medical Stocks For 2015

Best Medical Stocks For 2015: Atossa Genetics Inc (ATOS)

Atossa Genetics Inc., incorporated on April 30, 2009, is a development-stage healthcare company focused on the prevention of breast cancer through the commercialization of diagnostic tests that can detect precursors to breast cancer, and through the research, development, and ultimate commercialization of treatments for pre-cancerous lesions. The Company's diagnostic tests consist of medical devices cleared by the Food and Drug Administration (FDA), which can collect fluid samples from the breast milk ducts, where over 95% of breast cancers arise. During the fiscal year ended September 30, 2012, the tests that the Company offered and that are in development consist of ForeCYTE, ArgusCYTE, FullCYTE and NextCYTE. In September 2012, the Company acquired all of the assets of Acueity.

The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 73. The ArgusCYTE Breast Health Test provides information to help inform breast cancer treatment options and to help monitor potential recurrence. The FullCYTE Breast Health Test is designed to assess the individual breast ducts for pre-cancerous changes in women previously identified to be at high risk for breast cancer. The NextCYTE Breast Cancer Test is designed to profile breast cancer specimens for prediction of treatment outcomes and distant recurrence in women newly diagnosed with breast cancer. MASCT, Oxy-MASCT, and its name and logo are the trademarks. ForeCYTE, FullCYTE, NextCYTE, and ArgusCYTE are its service marks.

Advisors' Opinion:

• [By John Kell]

  Atossa Genetics Inc.(ATOS) is planning to offer shares and warrants to raise proceeds for general corporate purposes including the development of the company’s breast health testing products. Shares slumped 20% to $2.56 premarke! t.

• [By Bryan Murphy]

  You know, it's fun to be right about a particular stock, but at the same time, it's miserable if you didn't have the guts to actually act on the idea. That's my tale of woe with Atossa Genetics Inc. (NASDAQ:ATOS). On Monday of this week I was singing its praises, explaining how the chart suggested ATOS was on the verge of a breakout. But, I also suggested waiting for shares to take that one final confirming step.... a move above the 100-day moving average line. Now I wish I hadn't been so picky.

• [By James E. Brumley]

  I have little doubt that what I'm about to say could inflame some fans and followers of Atossa Genetics Inc. (NASDAQ:ATOS). But, I wouldn't be doing my job if I didn't call 'em like I see 'em. So, here goes. ATOS is on the verge of a substantial meltdown. It's possible the stock could circumvent this pullback, but the odds don't favor it.

• [By Roberto Pedone]

  One stock that's starting to push within range of triggering a big breakout trade is Apple (ATOS), which is involved in the prevention of breast cancer through the commercialization of diagnostic medical devices and laboratory developed tests that can detect precursors to breast cancer. This stock is off to a decent start in 2013, with shares up 24%.

  If you take a look at the chart for Atossa Genetics, you'll notice that this stock has been starting to uptrend over the last month, with shares moving higher from its low of $4.22 to its recent high of $5.08 a share. During that uptrend, shares of ATOS have been making mostly higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of ATOS within range of triggering a big breakout trade above a key downtrend line that dates back to May.

  Traders should now look for long-biased trades in ATOS if it manages to break out above some key overhead resistance levels at $5.08 a share with high volume. Look for a sustained move or close above ! that leve! l with volume that hits near or above its three-month average volume of 74,575 shares. If that breakout hits soon, then ATOS will set up to re-test or possibly take out its next major overhead resistance levels at $5.60 to $6.23 a share. Any high-volume move above $6.23 will then put $7 to $7.50 into range for shares of ATOS.

  Traders can look to buy ATOS off any weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $4.42 or at $4.22 a share. One could also buy ATOS off strength once it takes out $5.08 a share with volume and then simply use a stop that sits a comfortable percentage from your entry point.

source from Top Stocks For 2015:http://www.topstocksblog.com/best-medical-stocks-for-2015-3.html